Secondary resistance of gefitinib in non-small-cell lung cancer treatment
- VernacularTitle:吉非替尼在非小细胞肺癌治疗中的继发耐药
- Author:
Hui JI
;
Cuimin DING
- Publication Type:Journal Article
- Keywords:
Quinazolines;
Carcinoma,non-small-cell lung;
Drug resistance
- From:
Journal of International Oncology
2008;35(12):908-910
- CountryChina
- Language:Chinese
-
Abstract:
Gefitinib (iressa),an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,has antitumor activity in non-small-cell lung cancer (NSCLC).Despite the dramatic response to this inhibitor,most patients nevertheless ultimately have relapses because of the secondary resistance.In human lung adenocar-cinomas with EGFR mutation,a second-site point mutation that substitutes methionine for threonine at position 790(T790M) is associated with approximately half of cases of secondary resistance to gefitinib.Other mecha-nisras that contribute to gefitinib resistance include EGFR receptor internalization and MET gene amplification.
